Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | — |
The patient took Vivotif hour before the meal, but it was also 80 minutes after eating, the vaccine was supposed to be taken on an empty stomach; Case reference number US-BN-2025-000274 is a spontaneous case initially received from a consumer via Communications (reference number: USBAV25-0387) on 20-Feb-2025 and concerns a male patient of unknown age. The patient's medical history and concomitant medications were not provided. On unspecified date, the patient took a dose of Vivotif (batch number: unknown) at an unknown dose, route or site of administration for an unknown indication. As reported, the patient took Vivotif capsule one hour before the meal, but it was also 80 minutes after eating, the vaccine was supposed to be taken on an empty stomach (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A male patient of unknown age took Vivotif capsule one hour before the meal, but it was also 80 minutes after eating, the vaccine was supposed to be taken on an empty stomach which is currently considered as product administration error. Product administration error is considered listed per company conventions. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A male patient of unknown age took Vivotif capsule one hour before the meal, but it was also 80 minutes after eating, the vaccine was supposed to be taken on an empty stomach which is currently considered as product administration error. Product administration error is considered listed per company conventions. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's medical history and concomitant medications were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None